Integrated Filing — IndAS



General information about company

Scrip Code 500124
NSE Symbol DRREDDY
MSEI Symbol NOTLISTED
ISIN INE089A01031
Name of company Dr. Reddy's Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-05-2026   14:00:00
End date and time of board meeting 12-05-2026   15:47:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 23-01-2025
Indicate Company website link for updated RPT policy of the Company https://drreddys.com/cms/sites/default/files/media-library//Policy%20on%20Materiality%20of%20Related%20Party%20Transactions%20and%20Dealing%20with%20Related%20Party%20Transactions%20%281%29.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Notes are as per results published with SEBI



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,82,200.00 20,53,280.00
Other income 56,720.00 1,68,960.00
Total income 4,38,920.00 22,22,240.00
2 Expenses
(a) Cost of materials consumed 1,12,120.00 4,33,250.00
(b) Purchases of stock-in-trade 47,900.00 2,63,580.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 11,620.00 (23,050.00)
(d) Employee benefit expense 83,450.00 3,54,990.00
(e) Finance costs 5,430.00 14,830.00
(f) Depreciation, depletion and amortisation expense 31,850.00 1,20,740.00
(f) Other Expenses
1 Impairment of non current assets, net 12,110.00 14,050.00
2 Other expenses 1,64,990.00 6,18,720.00
Total other expenses 1,77,100.00 6,32,770.00
Total expenses 4,69,470.00 17,97,110.00
3 Total profit before exceptional items and tax (30,550.00) 4,25,130.00
4 Exceptional items 0.00 0.00
5 Total profit before tax (30,550.00) 4,25,130.00
6 Tax expense
7 Current tax (11,470.00) 91,770.00
8 Deferred tax 2,860.00 11,390.00
9 Total tax expenses (8,610.00) 1,03,160.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (21,940.00) 3,21,970.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (21,940.00) 3,21,970.00
17 Other comprehensive income net of taxes (5,400.00) (11,710.00)
18 Total Comprehensive Income for the period (27,340.00) 3,10,260.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,350.00 8,350.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 31,28,210.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.63 38.68
Diluted earnings (loss) per share from continuing operations -2.63 38.64
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.63 38.68
Diluted earnings (loss) per share from continuing and discontinued operations -2.63 38.64
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 7,75,270.00
Capital work-in-progress 1,36,910.00
Investment property
Goodwill 8,530.00
Other intangible assets 2,89,210.00
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 12,36,130.00
Trade receivables, non-current
Loans, non-current 50.00
Other non-current financial assets
1 Other non-current financial assets 26,860.00
Total of other non-current financial assets 26,860.00
Total non-current financial assets 12,63,040.00
Deferred tax assets (net)
Other non-current assets
1 Tax assets, net 26,500.00
2 Other non-current assets 8,430.00
Total of other non-current assets 34,930.00
Total non-current assets 25,07,890.00
2 Current assets
Inventories 4,95,560.00
Current financial asset
Current investments 3,23,350.00
Trade receivables, current 4,11,860.00
Cash and cash equivalents 33,750.00
Bank balance other than cash and cash equivalents 1,62,010.00
Loans, current 10,020.00
Other current financial assets
Total of other current financial assets 1,93,900.00
Total current financial assets 11,34,890.00
Current tax assets (net)
Other current assets
1 Other current assets 2,21,870.00
Total of other current assets 2,21,870.00
Total current assets 18,52,320.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 43,60,210.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,350.00
Other equity 31,28,210.00
Total equity attributable to owners of parent 31,36,560.00
Non controlling interest
Total equity 31,36,560.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 25,010.00
Total of other non-current financial liabilities 25,010.00
Total non-current financial liabilities 25,010.00
Provisions, non-current 1,200.00
Deferred tax liabilities (net) 58,990.00
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 24,200.00
Total of other non-current liabilities 24,200.00
Total non-current liabilities 1,09,400.00
Current liabilities
Current financial liabilities
Borrowings, current 5,41,900.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,160.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,87,260.00
Total Trade payable 1,90,420.00
Other current financial liabilities
1 Derivative instruments 67,850.00
2 Other financial liabilities 2,02,680.00
3 Lease liabilities 6,790.00
Total of other current financial liabilities 2,77,320.00
Total current financial liabilities 10,09,640.00
Other current liabilities 63,200.00
1 Other current liabilities 63,200.00
Total of other current liabilities 63,200.00
Provisions, current 30,690.00
Current tax liabilities (Net) 10,720.00
Deferred government grants, Current
Total current liabilities 11,14,250.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 12,23,650.00
Total equity and liabilites 43,60,210.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Global Generics 3,14,870.00 18,20,270.00
2 Pharmaceutical Services and Active Ingredients 83,500.00 2,97,500.00
3 Others 1,300.00 4,640.00
Total Segment Revenue 3,99,670.00 21,22,410.00
Less: Inter segment revenue 17,470.00 69,130.00
Revenue from operations 3,82,200.00 20,53,280.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Global Generics (31,410.00) 4,37,160.00
2 Pharmaceutical Services and Active Ingredients 670.00 (8,830.00)
3 Others 1,470.00 4,940.00
Total Profit before tax (29,270.00) 4,33,270.00
i. Finance cost 5,430.00 14,830.00
ii. Other Unallocable Expenditure net off Unallocable income (4,150.00) (6,690.00)
Profit before tax (30,550.00) 4,25,130.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Global Generics 0.00 0.00
2 Pharmaceutical Services and Active Ingredients 0.00 0.00
3 Others 0.00 0.00
Total Segment Asset 0.00 0.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 0.00 0.00
4 Segment Liabilities
Segment Liabilities
1 Global Generics 0.00 0.00
2 Pharmaceutical Services and Active Ingredients 0.00 0.00
3 Others 0.00 0.00
Total Segment Liabilities 0.00 0.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 0.00 0.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 1,340.00 1,340.00
Total Amount of items that will not be reclassified to profit and loss 1,340.00 1,340.00
2 Income tax relating to items that will not be reclassified to profit or loss 340.00 340.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (8,540.00) (16,980.00)
Total Amount of items that will be reclassified to profit and loss (8,540.00) (16,980.00)
4 Income tax relating to items that will be reclassified to profit or loss (2,140.00) (4,270.00)
5 Total Other comprehensive income (5,400.00) (11,710.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4,25,130.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 14,830.00
Adjustments for decrease (increase) in inventories (82,870.00)
Adjustments for decrease (increase) in trade receivables, current 1,82,780.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (4,470.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (8,890.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,20,740.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 14,050.00
Adjustments for provisions, current 44,880.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (31,170.00)
Adjustments for dividend income 0.00
Adjustments for interest income 77,710.00
Adjustments for share-based payments 2,990.00
Adjustments for fair value losses (gains) (20,520.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (20,740.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,750.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,35,650.00
Net cash flows from (used in) operations 5,60,780.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 94,730.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,66,050.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 57,910.00
Other cash receipts from sales of equity or debt instruments of other entities (4,13,540.00)
Other cash payments to acquire equity or debt instruments of other entities (1,49,680.00)
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2,580.00
Purchase of property, plant and equipment 2,04,920.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 9,800.00
Purchase of intangible assets 88,880.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 34,630.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (9,910.00)
Net cash flows from (used in) investing activities (5,78,470.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 3,970.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 2,02,810.00
Repayments of borrowings 0.00
Payments of lease liabilities 3,820.00
Dividends paid 66,590.00
Interest paid 24,690.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,11,680.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (740.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 2,520.00
Net increase (decrease) in cash and cash equivalents 1,780.00
Cash and cash equivalents cash flow statement at beginning of period 31,970.00
Cash and cash equivalents cash flow statement at end of period 33,750.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S.R.BATLIBOI & ASSOCIATES LLP Yes 31-07-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 1,800.00 Approved 820.00 0.00 11.00
2 Dr. Reddy's Laboratories Limited Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 7,500.00 Approved 3,769.00 0.00 0.00
3 Dr. Reddy's Laboratories Limited Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Purchase of goods or services 5,737.00 Approved 2,745.00 209.10 1.50
4 Dr. Reddy's Laboratories Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 562.00 Approved 258.70 3.20 7.80
5 Dr. Reddy's Laboratories Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 200.00 Approved 21.30 1.20 0.70
6 Dr. Reddy's Laboratories Limited Indus Projects Private Limited Entities with joint control or significant influence over entity Any other transaction Civil works 3,803.00 Approved 1,263.00 314.50 191.90
7 Dr. Reddy's Laboratories Limited K Satish Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 168.00 Approved 84.00 0.00 0.00
8 Dr. Reddy's Laboratories Limited K Samrajyam Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 24.20 Approved 12.10 0.00 0.00
9 Dr. Reddy's Laboratories Limited K Deepti Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 21.00 Approved 10.50 0.00 0.00
10 Dr. Reddy's Laboratories Limited G Anuradha Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 136.50 Approved 68.20 0.00 0.00
11 Dr. Reddy's Laboratories Limited G.V.Sanjana Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 31.50 Approved 15.70 0.00 0.00
12 Dr. Reddy's Laboratories Limited G.Mallika Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 26.30 Approved 13.10 0.00 0.00
13 Dr. Reddy's Laboratories Limited DRES Energy Private Limited Joint ventures where entity is venturer Purchase of goods or services 1,410.00 Approved 711.00 0.00 160.00
14 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Sale of goods or services 50,000.00 Approved 12,200.00 10,866.50 13,480.40
15 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 9,10,000.00 Approved 37,000.00 2,56,912.90 22,535.20
16 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 50,400.00 Approved 25,400.00 27,022.90 14,736.50
17 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 15,000.00 Approved 7,700.00 1,358.30 4,052.90
18 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Sale of goods or services 36,900.00 Approved 21,500.00 19,478.00 16,691.70
19 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Sale of goods or services 18,000.00 Approved (1,500.00) 11,350.10 (3,128.00)
20 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Sale of goods or services 2,90,000.00 Approved 1,63,700.00 56,314.10 61,024.10
21 Dr. Reddy's Laboratories Limited Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 14,000.00 Approved 0.00 6,426.20 2,528.20
22 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Sale of goods or services 30,000.00 Approved 9,400.00 22,040.50 20,373.50
23 Dr. Reddy's Laboratories Limited betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 41,000.00 Approved 21,100.00 16,853.80 6,105.60
24 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Holding-Subsidiary Sale of goods or services 10,000.00 Approved 2,400.00 3,901.60 2,592.60
25 Dr. Reddy's Laboratories Limited Reddy Pharma Iberia SAU, Spain Holding-Subsidiary Sale of goods or services 11,700.00 Approved 6,000.00 8,017.90 3,985.10
26 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Malaysia Sdn. Bhd., Malaysia Holding-Subsidiary Sale of goods or services 6,600.00 Approved 4,000.00 2,391.80 1,021.80
27 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Holding-Subsidiary Sale of goods or services 20,000.00 Approved 9,100.00 12,054.70 8,986.40
28 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SAS, Colombia Holding-Subsidiary Sale of goods or services 10,800.00 Approved 7,300.00 9,008.70 8,642.90
29 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 4,800.00 Approved 1,900.00 3,869.20 3,316.30
30 Dr. Reddy's Laboratories Limited Reddy Pharma SAS, France Holding-Subsidiary Sale of goods or services 7,000.00 Approved 4,700.00 231.70 2,586.90
31 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Sale of goods or services 20,000.00 Approved 7,400.00 4,842.20 2,200.00
32 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Sale of goods or services 1,20,000.00 Approved 5,100.00 5,860.70 1,106.90
33 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Thailand) Limited, Thailand Holding-Subsidiary Sale of goods or services 3,000.00 Approved 2,000.00 1,015.40 1,924.40
34 Dr. Reddy's Laboratories Limited Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Sale of goods or services 3,000.00 Approved 900.00 1,774.20 2,090.40
35 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Sale of goods or services 400.00 Approved 100.00 10.00 0.00
36 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Sale of goods or services 4,000.00 Approved 30.00 0.00 0.00
37 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Philippines Inc. Holding-Subsidiary Sale of goods or services 1,000.00 Approved 200.00 142.50 86.90
38 Dr. Reddy's Laboratories Limited Dr.Reddy’s laboratories Jamaica Limited Holding-Subsidiary Sale of goods or services 5,000.00 Approved 2,000.00 2,458.20 2,594.90
39 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Sale of goods or services 1,941.00 Approved 642.00 408.10 95,725.90
40 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Pharmaceuticals Joint ventures where entity is venturer Sale of goods or services 1,300.00 Approved 989.00 156.40 452.00
41 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Medical Company Joint ventures where entity is venturer Sale of goods or services 4,400.00 Approved 152.00 0.00 0.00
42 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 4,200.00 1,794.80 1,775.00
43 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 900.00 1,489.60 1,715.40
44 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 600.00 125.80 133.70
45 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Purchase of goods or services 15,000.00 Approved 4,100.00 2,177.50 807.50
46 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Purchase of goods or services 40,000.00 Approved 21,500.00 31,037.10 26,327.10
47 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Purchase of goods or services 8,000.00 Approved 5,400.00 2,781.70 2,781.70
48 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 5,900.00 1,360.40 4,002.60
49 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Purchase of goods or services 15,000.00 Approved 3,400.00 1,358.00 2,477.90
50 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Japan KK, Japan Holding-Subsidiary Purchase of goods or services 2,000.00 Approved 300.00 151.70 54.40
51 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Taiwan Limited, Taiwan Holding-Subsidiary Purchase of goods or services 400.00 Approved 200.00 152.10 129.50
52 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited, China Holding-Subsidiary Purchase of goods or services 5,000.00 Approved 2,700.00 1,247.10 203.40
53 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 5,600.00 51.30 221.50
54 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Purchase of goods or services 100.00 Approved 0.00 0.00 0.00
55 Dr. Reddy's Laboratories Limited Svaas Wellness Limited, India Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 1,000.00 137.10 0.00
56 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Purchase of goods or services 16,000.00 Approved 8,500.00 4,790.60 4,564.80
57 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Interest received 12,000.00 Approved 4,700.00 2,560.20 2,340.00
58 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Interest received 5.60 Approved 4.10 0.00 0.00
59 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Subsidiaries Interest received 22.00 Approved 22.00 0.00 0.00
60 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 40,000.00 Approved 18,000.00 0.00 0.00
61 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Commission on guarantee 500.00 Approved 300.00 123.00 189.80
62 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Any other transaction Rental income 500.00 Approved 124.00 94.80 86.20
63 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Rental income 1,000.00 Approved 436.00 235.00 0.00
64 Dr. Reddy's Laboratories Limited Idea2enterprises (India) Private Limited Holding-Subsidiary Any other transaction Rental Expense 140.00 Approved 69.00 26.40 24.00
65 Dr. Reddy's Laboratories Limited DRL Impex Limited Holding-Subsidiary Any other transaction Rental Expense 40.00 Approved 19.00 7.70 7.70
66 Dr. Reddy's Laboratories Limited Cheminor Investments Limited Holding-Subsidiary Any other transaction Rental Expense 20.00 Approved 9.00 3.30 3.30
67 Dr. Reddy's Laboratories Limited Dr. Reddy’s Bio-sciences Limited, India Holding-Subsidiary Any other transaction Rental Expense 90.00 Approved 44.00 8.80 8.80
68 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Any other transaction Pharmacy chain expenses reimbursement 23,500.00 Approved 11,400.00 (9,637.00) 8,183.40
69 Aurigene Discovery Technologies (Malaysia) SDN BHD Aurigene Oncology Limited, India Subsidiaries Sale of goods or services 500.00 Approved 136.00 234.00 186.90
70 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 4,000.00 Approved 400.00 (1,600.70) 149.00
71 betapharmArzneimittel GmbH, Germany Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 1,000.00 Approved 100.00 0.00 0.00
72 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories (UK) Limited, UK Subsidiaries Sale of goods or services 500.00 Approved 100.00 0.00 0.00
73 Dr. Reddy’s Laboratories (EU) Limited, UK Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 7,500.00 Approved 200.00 5,599.00 3,167.20
74 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Sale of goods or services 10,000.00 Approved 2,600.00 216.30 210.90
75 Dr. Reddy’s Laboratories Japan KK Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 500.00 Approved 0.00 0.00 0.00
76 Dr. Reddy’s Laboratories Romania SRL Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Sale of goods or services 14,000.00 Approved 4,300.00 7,772.70 5,988.70
77 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Sale of goods or services 7,300.00 Approved 6,600.00 0.00 0.00
78 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 2,50,000.00 Approved 1,04,000.00 1,21,461.40 1,20,538.00
79 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Kazakhstan LLP Subsidiaries Sale of goods or services 900.00 Approved 800.00 0.00 0.00
80 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Russia Subsidiaries Sale of goods or services 5,000.00 Approved 3,900.00 1,278.40 1,278.40
81 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Ukraine Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
82 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Romania SRL Subsidiaries Sale of goods or services 30,500.00 Approved 14,600.00 2,546.50 5,926.00
83 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s (Thailand) Limited, Thailand Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
84 Dr. Reddy’s Laboratories SA, Switzerland betapharmArzneimittel GmbH, Germany Subsidiaries Sale of goods or services 2,000.00 Approved 1,100.00 291.90 291.90
85 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Subsidiaries Sale of goods or services 4,000.00 Approved 1,400.00 217.30 1,140.70
86 Dr. Reddy’s Laboratories SAS, Colombia Dr. Reddy's Laboratories Chile SPA., Chile Subsidiaries Sale of goods or services 500.00 Approved 0.00 28.00 0.00
87 Dr. Reddy’s Srl Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 400.00 Approved 0.00 35.20 0.00
88 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 3,000.00 Approved 500.00 211.50 379.50
89 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Sale of goods or services 6,000.00 Approved 2,800.00 268.70 101.50
90 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 4,000.00 Approved 0.00 0.00 0.00
91 Reddy Pharma SAS, France Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 200.00 Approved 100.00 0.00 0.00
92 Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Dr. Reddy’s New Zealand Limited, New Zealand Subsidiaries Sale of goods or services 300.00 Approved 0.00 0.00 0.00
93 Aurigene Pharmaceutical Services Limited, India Aurigene Oncology Limited, India Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 146.50 250.10
94 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (UK) Limited Subsidiaries Sale of goods or services 25,000.00 Approved 12,100.00 3,845.90 1,887.70
95 Dr. Reddy’s Farmaceutica Do Brasil Ltda. Dr. Reddy's Laboratories Chile SPA., Chile Subsidiaries Sale of goods or services 4,000.00 Approved 0.00 51.80 50.10
96 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Subsidiaries Sale of goods or services 28,700.00 Approved 26,600.00 1,636.10 19,745.80
97 Dr. Reddy’s Laboratories SA, Switzerland Dr.Reddy’s Netherlands BV Subsidiaries Sale of goods or services 17,000.00 Approved 16,300.00 682.40 682.40
98 Reddy Pharma Iberia SAU, Spain Dr. Reddy’s Srl Subsidiaries Sale of goods or services 200.00 Approved 0.00 0.00 0.00
99 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma SAS, France Subsidiaries Sale of goods or services 5,000.00 Approved 0.00 0.00 0.00
100 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SAU, Spain Subsidiaries Sale of goods or services 2,000.00 Approved 0.00 0.00 0.00
101 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Subsidiaries Sale of goods or services 15,000.00 Approved 4,900.00 0.00 0.00
102 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Royalty Income 1,500.00 Approved 310.00 0.00 0.00
103 Aurigene Oncology Limited Aurigene Pharmaceutical Services Limited, India Subsidiaries Any other transaction Rental Income 500.00 Approved 200.00 434.00 33.00
104 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 200.00 Approved 100.00 5.90 2.00
105 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Any other transaction Other Income 200.00 Approved 0.00 0.00 0.00
106 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories (EU) Limited, UK Subsidiaries Any other transaction Other Income 0.00 Approved 0.00 0.00 0.00
107 Dr. Reddy’s Laboratories Inc., USA Aurigene Pharmaceutical Services Limited, India Subsidiaries Any other transaction Other Income 3,500.00 Approved 1,000.00 1,128.70 1,131.00
108 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 3,700.00 Approved 1,100.00 2,946.00 2,902.00
109 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Subsidiaries Any other transaction Other Income 37,500.00 Approved 18,000.00 646.70 849.70
110 Dr. Reddy`s Research and Development B.V. Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 1,500.00 Approved 500.00 646.70 213.00
111 Dr. Reddy’s Laboratories (Canada) Inc. Dr. Reddy’s Laboratories Inc., USA Subsidiaries Any other transaction Other Income 0.00 Approved 0.00 646.70 0.00
112 North Star OpCo Limited Dr. Reddy’s Laboratories (UK) Limited, UK Subsidiaries Any other transaction Other Income 1,500.00 Approved 0.00 471.80 415.50
113 Dr. Reddy’s Laboratories SA, Switzerland North Star OpCo Limited Subsidiaries Any other transaction Other Income 7,800.00 Approved 7,300.00 471.80 471.80
114 Aurigene Oncology Limited Aurigene Pharmaceutical Services Limited, India Subsidiaries Interest received 0.00 Approved 0.00 0.00 0.00
115 betapharmArzneimittel GmbH, Germany Nimbus Health GmbH Subsidiaries Interest received 50.00 Approved 0.00 0.00 0.00
116 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 2,700.00 Approved 1,201.00 0.00 0.00
117 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 200.00 Approved 13.00 0.00 0.00
118 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 2,400.00 Approved 732.00 0.00 0.00
119 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy`s Research and Development B.V. Subsidiaries Interest received 190.00 Approved 91.00 0.00 0.00
120 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Australia) Pty. Limited Subsidiaries Interest received 380.00 Approved 313.00 0.00 0.00
121 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy's Laboratories Philippines Inc. Subsidiaries Interest received 20.00 Approved 7.00 0.00 0.00
122 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories SAS, Colombia Subsidiaries Interest received 40.00 Approved 10.00 0.00 0.00
123 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Chile SPA., Chile Subsidiaries Interest received 40.00 Approved 20.00 0.00 0.00
124 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SA Subsidiaries Interest received 111.00 Approved 55.00 0.00 0.00
125 Lacock Holdings Limited Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 3.00 Approved 1.00 0.00 0.00
126 Dr. Reddy’s Laboratories SA, Switzerland Northstar OpCo Subsidiaries Interest received 24.00 Approved 0.00 0.00 0.00
127 Dr. Reddy’s Srl Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 138.00 Approved 74.00 0.00 0.00
128 Reddy Pharma SAS, France Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 82.00 Approved 22.00 0.00 0.00
129 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Subsidiaries Interest received 38.00 Approved 0.00 0.00 0.00
130 Reddy Netherlands B.V. Dr. Reddy`s Research and Development B.V. (formerly Octoplus BV) Subsidiaries Interest received 200.00 Approved 53.00 0.00 0.00
131 Northstar Switzerland SARL Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 2,524.00 Approved 1,803.00 0.00 0.00
132 North Star OpCo Limited Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 238.00 Approved 182.00 0.00 0.00
133 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Subsidiaries Interest received 525.00 Approved 82.00 0.00 0.00
134 Dr. Reddy’s Laboratories SA, Switzerland North Star Sweden AB Subsidiaries Interest received 2.00 Approved 1.00 0.00 0.00
135 Dr. Reddy's Laboratories Limited Naandi Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 38.00 0.00 0.00
136 Dr. Reddy's Laboratories Limited Wildlife Trust of India Entities with joint control or significant influence over entity Any other transaction Contributions for social development 113.00 Approved 49.00 0.00 0.00
137 Dr. Reddy's Laboratories Limited NICE Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 250.00 Approved 98.00 0.00 0.00
138 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Purchase 1,240.00 Approved 506.00 34.00 42.70
139 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Sale 90.00 Approved 43.00 26.00 162.50
140 Dr. Reddy's Laboratories Limited Indian School of Business Entities with joint control or significant influence over entity Any other transaction Campus placement, training and development services 120.00 Approved 118.00 0.00 0.00
141 Dr. Reddy’s Bio-sciences Limited, India DRES Energy Private Limited Joint ventures where entity is venturer Any other transaction Rental income 6.00 Approved 3.00 0.00 0.00
142 Aurigene Pharmaceutical Services Limited, India Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 20.00 Approved 0.00 0.00 0.00
143 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 150.00 0.00 0.00
144 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Annual facility maintenance cost Vaccine Development Lab 600.00 Approved 0.00 0.00 0.00
145 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Lab facility - Center of Excellence (CoE) for advanced and novel parenteral formulations 460.00 Approved 424.00 0.00 0.00
146 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 100.00 Approved 0.00 0.00 0.00
147 Aurigene Pharmaceutical Services Limited, India Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 20.00 Approved (10.00) 0.00 0.00
148 Aurigene Oncology Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 10.00 Approved 0.00 0.00 0.00
149 Aurigene Pharmaceutical Services Limited, India Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Purchase of goods or services 170.00 Approved 100.00 10.00 20.00
150 Aurigene Oncology Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 10.00 Approved 0.00 0.00 0.00
151 Aurigene Oncology Limited Clean Renewable Energy KK 2A Pvt Ltd Entities with joint control or significant influence over entity Purchase of goods or services 720.00 Approved 180.00 0.00 0.00
152 Aurigene Oncology Limited Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 30.00 Approved 0.00 0.00 0.00
153 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Manpower services provided by DRL India 8,045.00 Approved 3,314.00 0.00 0.00
154 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Marketing and promotional services provided by DRL India 1,811.00 Approved 205.00 0.00 0.00
155 Dr. Reddy's Laboratories Limited G V Prasad Key management personnel of entity or parent Remuneration 2,030.00 Approved 133.90 0.00 0.00
156 Dr. Reddy's Laboratories Limited K Satish Reddy Key management personnel of entity or parent Remuneration 1,260.00 Approved 133.90 0.00 0.00
157 Dr. Reddy's Laboratories Limited Deepak Sapra Key management personnel of entity or parent Remuneration 500.00 Approved 273.00 0.00 0.00
158 Dr. Reddy's Laboratories Limited Mannam Venkata Narasimham Key management personnel of entity or parent Remuneration 560.00 Approved 299.00 0.00 0.00
159 Dr. Reddy's Laboratories Limited M V Ramana Key management personnel of entity or parent Remuneration 900.00 Approved 474.00 0.00 0.00
160 Dr. Reddy's Laboratories Limited Krishna Venkatesh Key management personnel of entity or parent Remuneration 410.00 Approved 220.00 0.00 0.00
161 Dr. Reddy's Laboratories Limited Milan Kalawadia Key management personnel of entity or parent Remuneration 820.00 Approved 484.00 0.00 0.00
162 Dr. Reddy's Laboratories Limited Archana Bhaskar Key management personnel of entity or parent Remuneration 670.00 Approved 243.00 0.00 0.00
163 Dr. Reddy's Laboratories Limited Sanjay Sharma Key management personnel of entity or parent Remuneration 690.00 Approved 347.00 0.00 0.00
164 Dr. Reddy's Laboratories Limited Erez Israeli Key management personnel of entity or parent Remuneration 2,440.00 Approved 1,273.00 0.00 0.00
165 Dr. Reddy's Laboratories Limited Patrick Aghanian Key management personnel of entity or parent Remuneration 1,010.00 Approved 577.00 0.00 0.00
166 Dr. Reddy's Laboratories Limited Sushrut Kulkarni Key management personnel of entity or parent Remuneration 600.00 Approved 324.00 0.00 0.00
167 Dr. Reddy's Laboratories Limited Kumar Randhir Singh Key management personnel of entity or parent Remuneration 100.00 Approved 62.00 0.00 0.00
168 Dr. Reddy's Laboratories Limited Bhethanabottla S Phanimitra Key management personnel of entity or parent Remuneration 360.00 Approved 207.00 0.00 0.00
169 Dr. Reddy's Laboratories Limited Jayanth Sridhar Key management personnel of entity or parent Remuneration 390.00 Approved 214.00 0.00 0.00
170 Dr. Reddy's Laboratories Limited Akhil Ravi Relatives of Key management personnel Remuneration 150.00 Approved 86.00 0.00 0.00
171 Dr. Reddy's Laboratories Limited Vishal Reddy Relatives of Key management personnel Remuneration 50.00 Approved 4.00 0.00 0.00
172 Dr. Reddy's Laboratories Limited Shravya Reddy Kallam Relatives of Key management personnel Remuneration 20.00 Approved 13.00 0.00 0.00
173 Dr. Reddy's Laboratories Limited Aakar Asha Charitable Trust Entity in which director is interested directly/indirectly Any other transaction Contributions for social development 110.00 Approved 110.00 0.00 0.00
174 Dr. Reddy's Laboratories Limited Nayanta Education Foundation Entity in which director is interested directly/indirectly Any other transaction Contributions for social development 1,500.00 Approved 500.00 0.00 0.00
175 Dr. Reddy's Laboratories Limited International Foundation for Research and Education Entity in which director is interested directly/indirectly Any other transaction Contributions for social development 25.00 Approved 25.00 0.00 0.00
176 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories New York, LLC� Subsidiaries Any other transaction Asset purchase 800.00 Approved 79.00 0.00 0.00
Total value of transaction during the reporting period 7,08,637.50